Therapy for obesity based on gastrointestinal hormones
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Therapy for obesity based on gastrointestinal hormones. / Bagger, Jonatan I; Christensen, Mikkel; Knop, Filip K; Vilsboll, Tina.
In: Review of Diabetic Studies, Vol. 8, No. 3, 2011, p. 339-47.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Therapy for obesity based on gastrointestinal hormones
AU - Bagger, Jonatan I
AU - Christensen, Mikkel
AU - Knop, Filip K
AU - Vilsboll, Tina
PY - 2011
Y1 - 2011
N2 - It has long been known that peptide hormones from the gastrointestinal tract have significant impact on the regulation of nutrient metabolism. Among these hormones, incretins have been found to increase insulin secretion, and thus incretin-based therapies have emerged as new modalities for the treatment of type 2 diabetes. In contrast to other antidiabetic treatments, these agents have a positive outcome profile on body weight. Worldwide there are 500 million obese people, and 3 million are dying every year from obesity-related diseases. Recently, incretin-based therapy was proposed for the treatment of obesity. Currently two different incretin therapies are widely used in the treatment of type 2 diabetes: 1) the GLP-1 receptor agonists which cause significant and sustained weight loss in overweight patients, and 2) dipeptidyl peptidase 4 (DPP-4) inhibitors being weight neutral. These findings have led to a greater interest in the physiology of intestinal peptides with potential weight-reducing properties. This review discusses the effects of the incretin-based therapies in obesity, and provides an overview of intestinal peptides with promising effects as potential new treatments for obesity.
AB - It has long been known that peptide hormones from the gastrointestinal tract have significant impact on the regulation of nutrient metabolism. Among these hormones, incretins have been found to increase insulin secretion, and thus incretin-based therapies have emerged as new modalities for the treatment of type 2 diabetes. In contrast to other antidiabetic treatments, these agents have a positive outcome profile on body weight. Worldwide there are 500 million obese people, and 3 million are dying every year from obesity-related diseases. Recently, incretin-based therapy was proposed for the treatment of obesity. Currently two different incretin therapies are widely used in the treatment of type 2 diabetes: 1) the GLP-1 receptor agonists which cause significant and sustained weight loss in overweight patients, and 2) dipeptidyl peptidase 4 (DPP-4) inhibitors being weight neutral. These findings have led to a greater interest in the physiology of intestinal peptides with potential weight-reducing properties. This review discusses the effects of the incretin-based therapies in obesity, and provides an overview of intestinal peptides with promising effects as potential new treatments for obesity.
U2 - http://dx.doi.org/10.1900/RDS.2011.8.339
DO - http://dx.doi.org/10.1900/RDS.2011.8.339
M3 - Journal article
VL - 8
SP - 339
EP - 347
JO - The Review of Diabetic Studies
JF - The Review of Diabetic Studies
SN - 1613-6071
IS - 3
ER -
ID: 40219325